💊 Mycophenolate (Mycophenolate Mofetil)
Mycophenolate mofetil is an immunosuppressant used to prevent organ rejection in people who have received a kidney, heart or liver transplant, in combination with other immunosuppressants. It must be used under the supervision of a physician experienced in immunosuppressive therapy. It carries a boxed warning for embryofetal toxicity, malignancies and serious infections.
In Arabic: ميكوفينولات موفيتيل✅ What it is used for
- Prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney transplants
- Prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic heart transplants
- Prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic liver transplants
- Used in combination with other immunosuppressants
🧪 Active ingredient
The active ingredient is mycophenolate mofetil, which is converted in the body to mycophenolic acid. It inhibits an enzyme (IMPDH) needed for DNA synthesis in lymphocytes, reducing immune activity and helping prevent rejection of the transplanted organ.
🌿 Benefits
- Helps prevent rejection of transplanted kidney, heart or liver
- Can be used in children 3 months of age and older
📝 How to use
- The dose is set by your doctor or pharmacist only; do not change it without consulting them
- It is recommended to take on an empty stomach; in stable transplant patients it may be taken with food if necessary
- Once reconstituted, do not mix the oral suspension with any liquids before taking the dose
- Avoid inhaling or getting the powder on skin or mucous membranes; if contact occurs, wash thoroughly with soap and water, and rinse eyes with plain water
- If a dose is missed, take it as soon as remembered unless it is within 2 hours of the next dose; then continue at the usual times
- Do not interchange mycophenolate mofetil oral forms with mycophenolic acid delayed-release tablets without supervision of an experienced physician
💊 Dosage forms
- For oral suspension: 35 g mycophenolate mofetil powder (200 mg/mL upon reconstitution)
⚠️ Common side effects
- Diarrhea
- Leukopenia (low white blood cells)
- Infection
- Vomiting
🚨 Serious — seek medical help
- Serious infections, including opportunistic infections and reactivation of hepatitis B and C, which may be fatal
- Lymphoma and other malignancies, particularly of the skin
- Neutropenia and red blood cell aplasia
- Gastrointestinal complications such as bleeding, ulceration and perforation
- Hypersensitivity reactions including anaphylaxis
- Acute inflammatory syndrome associated with mycophenolate products
- Birth defects and first trimester pregnancy loss
⛔ Do not use if
- History of hypersensitivity, including anaphylaxis, to mycophenolate mofetil, mycophenolic acid or any component of the drug product
❗ Warnings & precautions
- Boxed warning: embryofetal toxicity, malignancies and serious infections
- Blood counts should be monitored; consider dose reduction or interruption for neutropenia
- Avoid use in patients with hypoxanthine-guanine phosphoribosyl-transferase deficiency
- Avoid live attenuated vaccines
- Oral suspension contains aspartame (caution in phenylketonurics)
- Avoid blood donation during therapy and for 6 weeks after, and semen donation during therapy and for 90 days after
- May affect the ability to drive or operate machinery
- Limit sun and UV exposure with protective clothing and sunscreen, especially if at increased risk of skin cancer
🔄 Drug interactions
- Antacids with magnesium or aluminum hydroxide: decrease exposure; give at least 2 hours after mycophenolate mofetil
- Proton pump inhibitors (e.g., lansoprazole, pantoprazole): may reduce efficacy
- Drugs that interfere with enterohepatic recirculation (e.g., cyclosporine A, trimethoprim/sulfamethoxazole, cholestyramine, rifampin, and certain antibiotic classes): may decrease exposure
- May reduce effectiveness of oral contraceptives; additional barrier methods are recommended
- Telmisartan and calcium-free phosphate binders may affect exposure (see full prescribing information)
🤰 Pregnancy
Use during pregnancy is associated with increased risk of first trimester pregnancy loss and multiple congenital malformations, including external ear and facial abnormalities (such as cleft lip and palate) and anomalies of the distal limbs, heart, esophagus, kidney and nervous system. Avoid during pregnancy if safer treatment options are available; females of reproductive potential must be counseled on pregnancy prevention and planning. Sexually active male patients and/or their female partners should use effective contraception during treatment and for at least 90 days after stopping. A pregnancy exposure registry exists (www.mycophenolateREMS.com).
🍼 Breastfeeding
The provided label text does not include information on breastfeeding; consult your doctor.
🧒 Children
Safety and effectiveness have been established in pediatric patients 3 months and older for prophylaxis of rejection of kidney, heart or liver transplants. Pediatric dosing is based on body surface area and is determined by the doctor.
👴 Older adults
Clinical studies did not include enough subjects aged 65 and over to determine whether they respond differently. Dose selection should consider decreased hepatic, renal or cardiac function and concomitant drug therapies.
🌡️ Storage
Store dry powder at 25°C (77°F); excursions permitted to 15°–30°C. Store constituted suspension at 25°C (excursions 15°–30°C) for up to 60 days; refrigeration at 2°–8°C is acceptable. Do not freeze. Wearing disposable gloves is recommended during reconstitution and when wiping the bottle and table.
⏰ Missed dose
Take the missed dose as soon as you remember, unless it is less than 2 hours before the next scheduled dose; in that case continue at the usual times. Do not double the dose.
🆘 Overdose
Possible signs include hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea, vomiting and dyspepsia. Seek medical help immediately if overdose is suspected. Bile acid sequestrants such as cholestyramine can increase removal of MPA; the drug is usually not removed by hemodialysis.
💰 Price & brands in your area
🏛️ Official price in Palestine — Ministry of Health price list:
| Product | Company | Pack | Price |
|---|---|---|---|
| MYCOPHENOLATE 500 MG 30TAB Mycophenolate 500mg | BPC | 30 Tab | 181 ₪ |
| MYCOPHENOLATE T.500MG (50 MYCOPHENOLATE | Teva | 50 tab | 316 ₪ |
| MYCOSOD 360 MG 60 TAB Mycophenolate Sodium Equivalent To 360 Mg of Mycophenolic Acid | BPC | 60Tab | 395 ₪ |
📍 Find the nearest pharmacy
Your location is used only in your browser to show nearby pharmacies — we don't store it.
Open in Google Maps👨⚕️ For healthcare professionals
Mechanism of action
MMF is absorbed and hydrolyzed to mycophenolic acid (MPA), a selective uncompetitive inhibitor of IMPDH types I and II, inhibiting de novo guanosine nucleotide synthesis and blocking DNA synthesis. MPA decreases T- and B-lymphocyte proliferative responses, antibody responses and cytokine production, and prevents glycosylation of adhesion glycoproteins. The effect is cytostatic and reversible.
Labeled dosing
General adult dosing per label: kidney transplant 1 g twice daily orally or IV; heart transplant 1.5 g twice daily; liver transplant 1.5 g twice daily orally or 1 g twice daily IV. Final dose and adjustments (renal impairment, neutropenia) are determined by the prescribing physician or pharmacist.
- Should not be used without supervision of a physician experienced in immunosuppressive therapy
- Oral MMF forms are not interchangeable with mycophenolic acid delayed-release tablets due to non-equivalent absorption
- Oral suspension may be given via nasogastric tube of at least 8 French
- IV formulation is an alternative when oral therapy is not tolerated; start within 24 hours post-transplant for up to 14 days
- Monitor blood counts; consider dose reduction or interruption for neutropenia
🎓 Key points for students
- Antimetabolite immunosuppressant that inhibits IMPDH
- Prodrug converted to active MPA; absolute oral bioavailability of 94% versus IV
- Boxed warning: embryofetal toxicity, malignancies, serious infections
- Key interactions: magnesium/aluminum antacids, PPIs, drugs affecting enterohepatic recirculation
- Most common adverse reactions (≥20%): diarrhea, leukopenia, infection, vomiting
- Contraindication: hypersensitivity to MMF or MPA
EME runs your whole clinic: appointments with WhatsApp reminders, patient files, finance & inventory, a patient portal and a members-price medical store — with your data isolated and protected.
Try EME free How we protect your data❓ FAQ
What is mycophenolate mofetil prescribed for?
To prevent rejection of a transplanted kidney, heart or liver, used together with other immunosuppressants.
Can I take it during pregnancy?
It is associated with increased risk of pregnancy loss and birth defects and should be avoided if safer options exist. Talk to your doctor before planning a pregnancy.
Does it affect birth control?
It may reduce the effectiveness of oral contraceptives; additional barrier methods are recommended.
How should I take it with antacids?
Take antacids containing magnesium or aluminum hydroxide at least 2 hours after mycophenolate mofetil.
What if I miss a dose?
Take it as soon as you remember, unless the next dose is due within 2 hours; then continue as usual.
Can I donate blood while taking it?
No. Avoid blood donation during treatment and for 6 weeks after, and semen donation for 90 days after.
⚕️ For education only — not a substitute for advice from your doctor or pharmacist. Do not start or stop any medicine without advice. Source: official FDA drug label via openFDA (2026-08), simplified. Updated: 2026-11-15.